Literature DB >> 7153839

Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin.

S Inouye, T Niizato, U Takeda, T Koeda.   

Abstract

Protection by fosfomycin of the nephrotoxicity of dibekacin was studied using Fischer 344 rats and urinary parameters such as volume, osmolality, protein, N-acetyl-beta-D-glucosaminidase, leucine aminopeptidase, lactate dehydrogenase and nucleated cells were determined as markers of nephrotoxicity. The duration of treatment was 11 d. Fosfomycin reduced polyuria, proteinuria, enzymuria and cyturia induced by dibekacin best by the concomitant administration, followed by pre-treatment, but not by post-treatment. Protection was effective in the dose ratio of dibekacin: fosfomycin = 1:2 - 1:32, regardless of administration routes. As judged from urinalysis, protection by fosfomycin (320 mg/kg) was almost complete for the experimental nephrotoxicity induced by 10 mg/kg of dibekacin, and still significant for that by 40 mg/kg. This was supported by the histo-pathological and ultrastructural improvement of proximal tubules and by suppressed blood urea nitrogen and creatinine values. Protective activity of fosfomycin was more potent than that of cephalothin, when compared on the weight basis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7153839     DOI: 10.1248/bpb1978.5.659

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  8 in total

Review 1.  Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients.

Authors:  Mojdeh S Heavner; Kimberly C Claeys; Anne M Masich; Jeffrey P Gonzales
Journal:  Curr Infect Dis Rep       Date:  2018-04-05       Impact factor: 3.725

Review 2.  Fosfomycin: Resurgence of an old companion.

Authors:  Sangeeta Sastry; Yohei Doi
Journal:  J Infect Chemother       Date:  2016-02-28       Impact factor: 2.211

3.  Influence of fosfomycin and tobramycin on vancomycin-induced nephrotoxicity.

Authors:  R Marre; E Schulz; D Hedtke; K Sack
Journal:  Infection       Date:  1985 Jul-Aug       Impact factor: 3.553

4.  Ceftriaxone protects against tobramycin nephrotoxicity.

Authors:  D Beauchamp; G Thériault; L Grenier; P Gourde; S Perron; Y Bergeron; L Fontaine; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

5.  Fosfomycin protects against tubulotoxicity induced by cis-diaminedichloroplatin and cyclosporin A in the rat.

Authors:  K Sack; E Schulz; R Marre; B Kreft
Journal:  Klin Wochenschr       Date:  1987-06-01

6.  Effects of fosfomycin, mesna, and sodium thiosulfate on the toxicity and antitumor activity of cisplatin.

Authors:  T Wagner; B Kreft; G Bohlmann; G Schwieder
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 7.  Aminoglycosides: nephrotoxicity.

Authors:  M P Mingeot-Leclercq; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

8.  Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.

Authors:  David L MacLeod; Lynn M Barker; Jennifer L Sutherland; Suzanne C Moss; Jesse L Gurgel; Thomas F Kenney; Jane L Burns; William R Baker
Journal:  J Antimicrob Chemother       Date:  2009-08-13       Impact factor: 5.790

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.